Full of Articles - Reference and Education

Plants, invertebrate animals, amphibians and even reptiles have the ability to regenerate lost or damaged body parts. In the case of lizards, for example, this is a defensive mechanism. When a predator attacks, the lizard can break off its own tail as a means of distraction. While the predator is busy eating the tail, the lizard escapes and regenerates the body part later on. Mammals can regenerate some skin and liver tissue, but our r

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

egenerative abilities stop there. Unlike lizards, which have nature to thank for their regenerative capabilities, we are dependent on scientists, physicians and the business community to develop new technologies that will help us repair and replace damaged tissue.

How do lizards and other animals regenerate tissue? Part of the answer has to do with stem cells. When an amphibian loses its tail, for example, stem cells in the spinal cor

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

d migrate into the regrowing tail and differentiate into several cell types, including muscle and cartilage. This occurs simultaneously with the growth and differentiation of cells in the tail stump. Eventually, this process results in a new, fully-functional and anatomically-correct tail.

The exact reasons why mammals are so limited when it comes to regenerative potential is still not known. However, there have been significant level

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

s of investment into stem cell research over the past several years in the hope of developing new technologies that will offer the ability to grow lost or damaged tissue, and perhaps even organs. Although there have been a number of recent breakthroughs in stem cell research, technologies that will actually regenerate human tissue are still several years away from fully coming to market. In the meantime, a new market is developing for

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

products that have the ability to interact with living tissue and in some cases promote cellular migration and growth. While these products stop well short of growing new limbs and organs, they do provide some solutions for many of the problems associated with traditional surgical and treatment options.

The surgical biomaterials market is currently one of the largest and fastest growing global medical markets. It encompasses a number

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

of surgical specialties and has reached a market capitalization of several billions dollars. The rapid growth of surgical biomaterials has to do with their capacity to reduce procedure times, recovery times and complication rates, while providing clinicians with innovative approaches to improving the level of patient care. Medical device companies worldwide are racing to bring to market biomaterial implants and devices that are designe

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

d to help repair defects in soft tissue, skin and bones.

What are biomaterials? A very broad definition of surgical biomaterials may include any substance that has the capacity to function in contact with living tissue and not be rejected by the body. This would include products made from metals, alloys and polyester-based materials such as orthopedic implants, and a number of other products traditionally used for the reconstruction o

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

r repair of tissue. The modern definition of surgical biomaterials, however, focuses on substances and products that not only evade rejection by the body, but that can interact with living tissue. These biomaterials do the job they are meant to perform, and then are either absorbed naturally by the body over time and eliminated by biological processes or become a permanent part of the surrounding tissue.

The use of nonviable materials

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

to repair or replace defects in the human body dates back thousands of years. Early civilizations such as the Egyptians, Romans and Aztecs used wood, ivory, gem stones and other objects to replace missing teeth and fill in bone defects more than 2,500 years ago. Since then, scientific developments have led to the use of a number of different synthetics and natural materials in the human body. From World War I through World War II a nu

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

mber of natural rubbers, celluloids, vinyl polymers and polyurethanes were used for grafts, artificial hearts and catheters. During World War II, silicon was used in Japan to enhance the breasts of prostitutes and polymethylmethacrylate (PMMA), the main component in many of today’s bone cements, was used in dental and craniofacial applications. Alloys have been used as pins and plates in the human body since the early nineteenth centur

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

y. The use of steel and other alloys, which have the tendency to discolor, eventually led to the development and introduction of stainless steel and titanium, materials that are still commonly used in the production of orthopedic implants today.

Biomaterials can be made either from synthetic compounds or natural substances. Synthetic materials such as hydroxyapatite and tricalcium phosphate have been used for years in dental, craneo-m

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

axilofacial and orthopedic procedures. The use of natural substances such as human or animal tissue in the manufacture of surgical biomaterials is a more recent development. A number of years of research and development in this area have led to technological advances in the processing of natural tissue to remove its toxicity and improve its clinical properties. Natural substances generally have complex structures that are difficult to

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

replicate with synthetic compounds, and therefore can interact with human tissue in ways that synthetic products cannot. The ongoing development of surgical biomaterials is now resulting in a number of hybrid products that integrate both natural and synthetic substances in an effort to provide products that offer the clinical benefits of both materials.

Some of the benefits of biomaterials can be seen in their use in surgeries that ty

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

pically use “autografts”. This is when surgeons take tissue (or bone) from one part of the patient’s body and then place it in another part of their body in order to repair a defect or replace diseased tissue. One of the most common procedures in which autografts are used is spinal fusion, a surgery in which one or more vertebrae of the spine are welded together with the aim of eliminating painful motion. During a spinal fusion, the su

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

rgeon makes an incision in the patient’s hip and removes a piece of bone from the pelvis, which is then implanted in the space between the vertebrae and held in place by metal fasteners. The pain and problems associated with motion are reduced over time, as the implanted bone and vertebrae grow into a single, solid bone. Some of the major disadvantages of autografts in these procedures are the additional operating time it takes the sur

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

geon to harvest the graft, the extra postoperative recovery time needed and the added pain the patient must endure at the harvest site. Synthetic or animal based biomaterial bone substitutes provide surgeons and their patients with an option that lessens time under anesthesia and cuts down on recovery time.

Collagen implants for tissue repair and augmentation is another area where biomaterials may offer substantial benefits over tradi

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

tional treatments. In recent years, the use of membranes made from natural substances such as porcine and bovine dermis or pericardium has gained in popularity with surgeons. Synthetic membranes made from materials such as polypropylene, polyester, silicone or polytetrafluoroethylene (PTFE) have been widely used in facial aesthetic and reconstructive surgery, hernia repair, neurosurgery and other surgical procedures. While synthetic su

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

rgical meshes have good strength characteristics, they remain in the body as permanent implants and sometimes can cause adverse reactions when the surrounding tissue identifies these materials as foreign bodies. A handful of companies in Europe and the U.S. have developed new ways of collecting and processing animal collagen to produce membranes that offer the same strength characteristics as synthetic membranes, but are completely bio

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

compatible and provide a permanent solution for the repair and augmentation of tissue. Since the structure of this collagen is so similar to human tissue, once it is implanted the membrane provides the basis for cellular ingrowth and revascularization.

Bone graft substitutes and collagen implants do not have the capacity to help us grow new limbs or organs. However, they are an important step in the ongoing developments being made in

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

the fields of tissue engineering and regenerative medicine. Progress continues to be made into stem cell research and, just like amphibians and lizards, one day new technologies may be available to help us regenerate our bodies. In the meantime, the market for surgical biomaterials continues to evolve and new technologies are continuously coming to market that have the capacity to improve the quality of life of mammals around the world

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.fullofarticles.org.ua/article/223587/fullofarticles-Surgical-Biomaterials-and-Tissue-Regeneration-Technologies.html">Surgical Biomaterials and Tissue Regeneration Technologies</a>

BB link (for phorums):
[url=http://www.fullofarticles.org.ua/article/223587/fullofarticles-Surgical-Biomaterials-and-Tissue-Regeneration-Technologies.html]Surgical Biomaterials and Tissue Regeneration Technologies[/url]

Sooner or later, it happens to every business owner. A customer, that you thought was really great because they praised and flattered you, has suddenly turned into the most difficult customer you have.

Once you have completed your web site development and design, you're ready to start website marketing. The foundation for creating advertising copy or website writing that floods your newly designed website’s copy with cash-in-hand ready-to-buy customers is forged from the interview process between you and your copywriter. Subsequent research and the creation of a dynamite promotion all stems from the critical information gathered about your business, your product and service, your customers and your competition. The answers to the questions below are crucial to the effective and successful completion of your project.

Gamasutra is a site which says it's all about 'The Art & Business of Making Games'. I know at one point in my life I've wondered about how cool it would be to create the next Grand Theft Auto or Crash Bandicoot.

Tags

Links

Full of Articles - Surgical Biomaterials and Tissue Regeneration Technologies

Related Articles: